Form 8-K - Current report:
SEC Accession No. 0001601485-24-000074
Filing Date
2024-11-13
Accepted
2024-11-13 16:10:04
Documents
19
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K angn-20241113.htm   iXBRL 8-K 23856
2 EX-99.1 q3earnings_prx11-12x24xf.htm EX-99.1 18738
6 q3earnings_prx11-12x24xf001.jpg GRAPHIC 224519
7 q3earnings_prx11-12x24xf002.jpg GRAPHIC 215257
8 q3earnings_prx11-12x24xf003.jpg GRAPHIC 129990
9 q3earnings_prx11-12x24xf004.jpg GRAPHIC 258326
10 q3earnings_prx11-12x24xf005.jpg GRAPHIC 271524
  Complete submission text file 0001601485-24-000074.txt   1694844

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20241113.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20241113_lab.xml EX-101.LAB 22786
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20241113_pre.xml EX-101.PRE 13130
22 EXTRACTED XBRL INSTANCE DOCUMENT angn-20241113_htm.xml XML 2907
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 241454243
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)